Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2830
Peer-review started: August 31, 2014
First decision: September 27, 2014
Revised: November 13, 2014
Accepted: December 1, 2014
Article in press: December 1, 2014
Published online: March 7, 2015
Processing time: 191 Days and 4.8 Hours
Gastric carcinosarcomas are rare morphologically biphasic tumors, consisting of carcinoma and sarcoma components, with a poor clinical course. Here we report the case of a 70-year-old man with advanced Borrmann type III carcinosarcoma arising from the upper body of the stomach with extensive lymph node metastasis who underwent a total, but palliative, gastrectomy. Histology showed the tumor consisted of a biphasic structure of tubular adenocarcinoma and spindle cell sarcoma. Immunohistochemistry revealed sarcoma cells expressing c-kit (CD117) and CD34, which are criteria for gastrointestinal stromal tumors. Nine months after the surgical operation, tumor metastases had extended to the hepatohilar, retroperitoneal and mediastinal lymph nodes. Radiation therapy of 50 Gy markedly decreased the size of each of these nodes and reduced the risk of respiratory complications and jaundice. However, the patient died of respiratory failure due to bronchopneumonia with multiple lung metastases 22 mo after resection. Autopsy revealed severe necrosis in most of the lymph nodes with tumor metastases. Radiation therapy combined with gastrectomy should be considered to improve survival in patients with gastric carcinosarcomas that express c-kit.
Core tip: Gastric carcinosarcoma is a rare tumor for which there is no established definitive treatment. We present the first report of gastric carcinosarcoma with c-kit expression treated with neoadjuvant chemotherapy, surgical resection and radiation therapy. Radiation therapy to the metastatic tumors dramatically reduced their size and the patient survived 22 mo after surgery with a good quality of life. Although the relation between c-kit expression and radiation susceptibility remains unknown, this report provides new insight into the treatment of gastric carcinosarcoma for improved prognosis.